loxapine
Sign in to saveLoxapine, sold under the brand names Loxitane and Adasuve (inhalation only) among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. It is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.
Key facts
- Drug.UNII
- LER583670J
- Drug.KEGG
- D02340
- Drug.ChEBI
- 50841
- Drug.ChEMBL
- 831
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 408581688
- Drug.image
- Loxapine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Loxapine ball-and-stick model from xtal 1977.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 200
- Drug.tradename
- Loxitane, Adasuve
- Drug.MedlinePlus
- a682311
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Loxapine
- Drug.licence_US
- Loxapine
via Wikipedia infobox
Article
10 sectionsContents
- Medical uses
- Available forms
- Side effects
- Pharmacology
- Mechanism of action
- Use as an inhaled agitation medication
- Pharmacokinetics
- Chemistry
- References
- External links
Loxapine, sold under the brand names Loxitane and Adasuve (inhalation only) among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. It is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.
Loxapine may be metabolized by N-demethylation to amoxapine, a tricyclic antidepressant.
Gallery (4)
Connections
Categories
4-Methylpiperazin-1-yl compoundsAlpha-1 blockersAlpha-2 blockersChloroarenesDibenzoxazepinesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs with non-standard legal statusECHA InfoCard ID from WikidataHallucinogen antidotesM1 receptor antagonists